Follicum is developing pharmaceuticals from endogenous peptides that have been modified. These peptides can both stimulate and inhibit the performance of hair follicles, directly affecting the way they work. Because these are based on endogenous peptides, i.e. those found naturally in the human body, Follicum believe they will make safe, gentle and efficacious treatments.
The development of these peptides into drugs requires that they go through the same rigorous process of clinical trials as other regulated products. This ensures that the promised effect really exists, and has been proven in independent double-blind clinical trials. This is not the case for many of the products available on the market today.
Follicum’s main income is expected to come from out-licensing or sale of all or part of the company’s pharmaceutical projects to pharmaceutical companies and/or financial investors, after having entered into clinical development. Follicum does not intend to set up a sales organization for the sale of pharmaceutical products.